Abstract
Leukotrienes are one of the major eicosanoid lipid mediators produced due to an oxidative transformation of arachidonic acid. Subsequently, they get converted into various cellular signaling hormones by a series of enzymes of myeloid origin to mediate or debilitate inflammation. Interestingly, the available literature demonstrates the pivotal role of eicosanoids in neurodegenerative, obesity, diabetes, cardiovascular diseases, and cancers as well. The aberrant metabolism of arachidonic acid by the LOX pathway is a common feature of epithelial-derived malignancies and suggests the contributory role of dietary fats in carcinogenesis. The enzymes and receptors of the LOX pathway play a significant role in cell proliferation, differentiation and regulation of apoptosis through multiple signaling pathways and have been reported to be involved in various cancers, including prostate, colon, lung and pancreatic cancers. So far, leukotriene receptor antagonists and 5-LOX inhibitors have reached up to the clinical trials for treating various diseases. Keeping its various roles in cancer, the review highlights the components of the leukotriene synthesizing machinery, emerging opportunities for pharmacological intervention, and the probability of considering lipoxygenases and leukotriene receptors as good candidates for clinical chemoprevention studies.
Keywords: Eicosanoid, arachidonic acid, leukotrienes, lipoxygenases, cancer, lipoxygenase inhibitors, leukotriene hydroxylase, cysteinyl leukotriene receptor, phytochemicals.
Current Pharmaceutical Design
Title:Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Volume: 27 Issue: 31
Author(s): P. Vishnupriya, A. Aparna and Vijaya P. Viswanadha*
Affiliation:
- Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu 641046,India
Keywords: Eicosanoid, arachidonic acid, leukotrienes, lipoxygenases, cancer, lipoxygenase inhibitors, leukotriene hydroxylase, cysteinyl leukotriene receptor, phytochemicals.
Abstract: Leukotrienes are one of the major eicosanoid lipid mediators produced due to an oxidative transformation of arachidonic acid. Subsequently, they get converted into various cellular signaling hormones by a series of enzymes of myeloid origin to mediate or debilitate inflammation. Interestingly, the available literature demonstrates the pivotal role of eicosanoids in neurodegenerative, obesity, diabetes, cardiovascular diseases, and cancers as well. The aberrant metabolism of arachidonic acid by the LOX pathway is a common feature of epithelial-derived malignancies and suggests the contributory role of dietary fats in carcinogenesis. The enzymes and receptors of the LOX pathway play a significant role in cell proliferation, differentiation and regulation of apoptosis through multiple signaling pathways and have been reported to be involved in various cancers, including prostate, colon, lung and pancreatic cancers. So far, leukotriene receptor antagonists and 5-LOX inhibitors have reached up to the clinical trials for treating various diseases. Keeping its various roles in cancer, the review highlights the components of the leukotriene synthesizing machinery, emerging opportunities for pharmacological intervention, and the probability of considering lipoxygenases and leukotriene receptors as good candidates for clinical chemoprevention studies.
Export Options
About this article
Cite this article as:
Vishnupriya P., Aparna A. and Viswanadha P. Vijaya *, Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer, Current Pharmaceutical Design 2021; 27 (31) . https://dx.doi.org/10.2174/1381612826666210101153216
DOI https://dx.doi.org/10.2174/1381612826666210101153216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients
Current Aging Science Cell Death in Mammalian Development
Current Pharmaceutical Design Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Rational Design and Intramolecular Cyclization of Hotspot Peptide Segments at YAP–TEAD4 Complex Interface
Protein & Peptide Letters Marine Derived Bioactive Compounds for Breast and Prostate Cancer Treatment: A Review
Current Bioactive Compounds Pictorial US, CT and MRI Findings of Common Hepatic Tumours
Current Medical Imaging Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets The Evolution of Diagnosis and Management of Pediatric Biliary Tract Rhabdomyosarcoma
Current Pediatric Reviews Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Alkaloids and Flavonoids as α1-Adrenergic Receptor Antagonists
Current Medicinal Chemistry